Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial

Sarris, Andreas H.; Hagemeister, Frederick; Romaguera, Jorge; Rodríguez, Maritza; McLaughlin, Peter; Tsimberidou, Apostolia M.; Medeiros, L. Jeffery; Samuels, Barry I; Pate, Odeal; Oholendt, M.; Kantarjian, Hagop M.; Burge, C.; Cabanillas, Fernando

doi:10.1023/a:1008348010437

Cited by 130 publications

(48 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 ± 31 These findings were subsequently extended and confirmed in Phase I/II clinical trials, which have demonstrated the beneficial effects of liposome encapsulation in regard to improved pharmacokinetics and antitumor activity of liposomal vincristine in humans. 32,33 The improved antitumor efficacy of SALP over free [ S] ODNs is consistent with the increased tumor accumulation and homogeneous distribution of [ S] ODNs within the NG tumors. The broad distribution of SALP/ FITC ± [ S] ODNs within the NG tumor mass was confirmed using LSCM analysis.…”

Section: Discussionmentioning

confidence: 57%

Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line

Leonetti¹,

Biroccio²,

Benassi³

et al. 2001

Cancer Gene Ther

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 57%

Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line

Leonetti¹,

Biroccio²,

Benassi³

et al. 2001

Cancer Gene Ther

View full text Add to dashboard Cite

“…In addition to the licensed anthracyclines, other liposome-encapsulated cytotoxic agents are undergoing clinical assessment. Examples include various liposomal camptothecins in early-stage clinical trials (16,17) and liposomal vincristine, demonstrating positive results in refractory patient populations (18,19).…”

Section: Introductionmentioning

confidence: 99%

Liposomal Irinotecan

Messerer

Ramsay

Waterhouse

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose:The purpose is to demonstrate whether an appropriately designed liposomal formulation of irinotecan is effective in treating mice with liver-localized colorectal carcinomas.Experimental Design: Irinotecan was encapsulated in 1,2-distearoyl-sn-glycero-3-phosphocholine/cholesterol (55:45 molar ratio) liposomes using an ionophore (A23187)-generated transmembrane proton gradient. This formulation was evaluated in vivo by measuring plasma elimination of liposomal lipid and drug after i.v. administration. Therapeutic activity was determined in SCID/Rag-2M mice bearing s.c. LS180 tumors or orthotopic LS174T colorectal metastases.Results: Drug elimination from the plasma was significantly reduced when irinotecan was administered in the liposomal formulation. At 1 hour after i.v. administration, circulating levels of the liposomal drug were 100-fold greater than that of irinotecan given at the same dose. High-performance liquid chromatographic analysis of plasma samples indicated that liposomal irinotecan was protected from inactivating hydrolysis to the carboxylate form. This formulation exhibited substantially improved therapeutic effects. For the LS180 solid tumor model, it was shown that after a single injection of liposomal irinotecan at 50 mg/kg, the time to progress to a 400-mg tumor was 34 days (as compared with 22 days for animals treated with free drug at an equivalent dose). In the model of colorectal liver metastases (LS174T), a median survival time of 79 days was observed after treatment with liposomal irinotecan (50 mg/kg, given every 4 days for a total of three doses). Saline and free drug treated mice survived for 34 and 53 days, respectively.Conclusions: These results illustrate that liposomal encapsulation can substantially enhance the therapeutic activity of irinotecan and emphasize the potential for using liposomal irinotecan to treat liver metastases.

show abstract

“…15 Clinical studies using VCR encapsulated in distearoylphospatidylcholine/cholesterol (DSPC/Chol) demonstrated that liposomal VCR can be administered at higher doses than free drug and it is effective in relapsed non-Hodgkin's lymphomas (NHL). 16,17 A modification of DSPC/Chol liposomes has been introduced generating the sphingomyelin/cholesterol (SM/Chol) liposomes. The SM/Chol liposomal formulation further improves the pharmacokinetic parameters of VCR, producing an increased VCR accumulation in peritoneal ascitic murine P388 tumors and in solid tumors compared to DSPC/Chol liposome VCR.…”

mentioning

confidence: 99%

In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumors

Leonetti

Scarsella²,

Semple

et al. 2004

Intl Journal of Cancer

View full text Add to dashboard Cite

Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial

Cited by 130 publications

References 12 publications

Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line

Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line

Liposomal Irinotecan

In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumors

Contact Info

Product

Resources

About